Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)
- Authors
- Garon, E.B.[Garon, E.B.]; Cho, B.C.[Cho, B.C.]; Reinmuth, N.[Reinmuth, N.]; Lee, K.H.[Lee, K.H.]; Luft, A.[Luft, A.]; Ahn, M.-J.[Ahn, M.-J.]; Robinet, G.[Robinet, G.]; Le, Moulec S.[Le, Moulec S.]; Natale, R.[Natale, R.]; Schneider, J.[Schneider, J.]; Shepherd, F.A.[Shepherd, F.A.]; Garassino, M.C.[Garassino, M.C.]; Geater, S.L.[Geater, S.L.]; Szekely, Z.P.[Szekely, Z.P.]; Van, Ngoc T.[Van, Ngoc T.]; Liu, F.[Liu, F.]; Scheuring, U.[Scheuring, U.]; Patel, N.[Patel, N.]; Peters, S.[Peters, S.]; Rizvi, N.A.[Rizvi, N.A.]
- Issue Date
- Jul-2021
- Publisher
- Elsevier Inc.
- Keywords
- Functioning; Health status; Immunotherapy; Quality of life; Symptoms
- Citation
- CLINICAL LUNG CANCER, v.22, no.4, pp.301 - +
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL LUNG CANCER
- Volume
- 22
- Number
- 4
- Start Page
- 301
- End Page
- +
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/24992
- DOI
- 10.1016/j.cllc.2021.02.010
- ISSN
- 1525-7304
- Abstract
- Background: The phase 3 MYSTIC study of durvalumab ± tremelimumab versus chemotherapy in metastatic non–small-cell lung cancer (NSCLC) patients with tumor cell (TC) programmed cell death ligand 1 (PD-L1) expression ≥ 25% did not meet its primary endpoints. We report patient-reported outcomes (PROs). Patients and Methods: Treatment-naïve patients were randomized (1:1:1) to durvalumab, durvalumab + tremelimumab, or chemotherapy. PROs were assessed in patients with PD-L1 TC ≥ 25% using EORTC Quality of Life Questionnaire (QLQ)-C30/LC13. Changes from baseline (12 months) for prespecified PRO endpoints of interest were analyzed by mixed model for repeated measures (MMRM) and time to deterioration (TTD) by stratified log-rank tests. Results: There were no between-arm differences in baseline PROs (N = 488). Between-arm differences in MMRM-adjusted mean changes from baseline favored at least one of the durvalumab-containing arms versus chemotherapy (nominal P < .01) for C30 fatigue: durvalumab (−9.5; 99% confidence interval [CI], −17.0 to −2.0), durvalumab + tremelimumab (−11.7; 99% CI, −19.4 to −4.1); and for C30 appetite loss: durvalumab (−11.9; 99% CI, −21.1 to −2.7). TTD was longer with at least one of the durvalumab-containing arms versus chemotherapy (nominal P < .01) for global health status/quality of life: durvalumab (hazard ratio [HR] = 0.7; 95% CI, 0.5-1.0), durvalumab + tremelimumab (HR = 0.7; 95% CI, 0.5-1.0); and for physical functioning: durvalumab (HR = 0.6; 95% CI, 0.4-0.8), durvalumab + tremelimumab (HR = 0.6; 95% CI, 0.5-0.9) (both C30); as well as for the key symptoms of dyspnea: durvalumab (HR = 0.6; 95% CI, 0.5-0.9), durvalumab + tremelimumab (HR = 0.7; 95% CI, 0.5-1.0) (both LC13); fatigue: durvalumab + tremelimumab (HR = 0.6; 95% CI, 0.4-0.8); and appetite loss: durvalumab (HR = 0.5; 95% CI, 0.4-0.7), durvalumab + tremelimumab (HR = 0.7; 95% CI, 0.5-0.9) (both C30). Conclusion: Durvalumab ± tremelimumab versus chemotherapy reduced symptom burden and improved TTD of PROs, suggesting it had no detrimental effects on quality of life in metastatic NSCLC patients. We investigated the impact of durvalumab ± tremelimumab versus chemotherapy on patient-reported symptoms, functioning, and global health status/quality of life in the phase 3 MYSTIC trial of metastatic non–small-cell lung cancer in patients with tumor cell programmed cell death ligand 1 expression ≥ 25%. Durvalumab ± tremelimumab reduced symptom burden and improved times to deterioration, suggesting there were no detrimental effects with treatment. © 2021 The Authors
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.